Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention
Intravacc - intranasally administered OMV Key mode of action of intranasally administered OMVs. Mucosal route induces both localized and systemic...
Clinical Trial
Sequana Medical announces H1 2023 results and provides business update
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION14 September 2023, 07:00 CEST alfapump® – strong pivotal POSEIDON data presented at leading international...
BioSenic reaches agreement on binding term sheets with main creditors to restructure past financial debts
INSIDE INFORMATION New binding term sheets have been formulated upon for the replacement of the Monument and Patronale bonds and...
Pharmazz Inc. and Sun Pharma enter into licensing agreement for introducing Tyvalzi™ (Sovateltide) in India
Sovateltide is a first of its kind drug to treat acute cerebral ischemic stroke that can be administered up to...
Awakn Life Sciences Provides Corporate Update
Announces Closing of Third Tranche of Private PlacementToronto, Ontario--(Newsfile Corp. - September 14, 2023) - Awakn Life Sciences Corp. (NEO:...
Zomedica Provides Corporate Update
ANN ARBOR, MI / ACCESSWIRE / September 13, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
New patent issued to Napo Pharmaceuticals, a Jaguar Health family company, for core rare disease target indication for crofelemerJaguar is...
Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis
LIEGE, BELGIUM / ACCESSWIRE / September 13, 2023 / Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new...
Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers...
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
PALO ALTO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary...
Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine
Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)ALBANY, N.Y., Sept. 13,...
NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase
CARMEL, Ind., Sept. 13, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology...
HOOKIPA Announces Executive Leadership Change
NEW YORK and VIENNA, Sept. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a...
NurExone Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with the FDA for Proprietary ExoPTEN Drug
The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines and large-scale animal studies will...
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests...
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the...
Congenica and myTomorrows Announce Partnership to Advance Precision Oncology by Facilitating Rapid Access to Clinical Trials
AMSTERDAM and NEW YORK, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Congenica, a leading digital health company specializing in the provision...
Recce Pharmaceuticals Secures $8M Placement and Launches $3M Entitlement Offer to Shareholders
$8 million commitments received in a strongly supported placement to new and existing institutional investors $3 million entitlement offer at the...
PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023
Company to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA®PRINCETON, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- PDS...
Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023
RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Science 37 announced today that it has been recognized in...